Sandoz targets 100+ biosimilars by 2040 with new $300 million Slovenia facility

Sandoz has announced its “Bio100” strategy:
it aims to expand its biosimilar portfolio from 13 products today to more than 100 by 2040.

The company wants biosimilars to become the majority of its sales and plans to more than double net sales between 2025 and 2035.

For 2025–2030, Sandoz is targeting mid- to high-single-digit annual net-sales growth at constant exchange rates, with a core EBITDA margin of 25%–27% by 2030.

By 2035, it aims to cover roughly 80% of the value of biosimilars facing loss of exclusivity, up from about 50% currently, and achieve a core EBITDA margin above 30%.

Sandoz will invest approximately $300 million in a new biosimilar drug-substance facility in Ljubljana, Slovenia. Expected to be operational in 2029, it will add 8,000 litres of capacity through four disposable fed-batch reactors.

The facility is intended to improve flexibility for lower- and medium-volume production and strengthen Sandoz’s end-to-end European biosimilar network. The announcement follows more than $1.1 billion of broader investment in Slovenia.